AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25888092 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 98
Study 25888092 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pethidine and placebo)
Number of subjects: 98
Study 23094932 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy 1 h/week for 12 weeks
Number of subjects: 90
Study 23094932 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment for the same time period
Number of subjects: 90
Study 20022457 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular infiltration of corticosteroid, opioid, and a local anesthetic
Number of subjects: 40
Study 18517074 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 73
Study 18517074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 16099715 — intervention group
Group type: EXPERIMENTAL
Intervention: 15mg sibutramine (SB) at bedtime for 1 month
Number of subjects: 21
Study 16099715 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) at bedtime for 1 month
Number of subjects: 21
Study 12453973 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled regular insulin (INH) via Aerodose Insulin Inhaler, 240 units
Number of subjects: 15
Study 12453973 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled regular insulin (INH)
Number of subjects: 15
Study 12453973 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneously injected regular insulin (SC)
Number of subjects: 15
Study 10624751 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth taped closed
Number of subjects: 9
Study 10624751 — intervention group
Group type: COMPARATOR
Intervention: Ventilator-induced awake hypopharyngeal pressure swing during timed bilevel ventilation
Number of subjects: 9
Study 7586605 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH1-29NH2 (1 microgram/kg BW)
Number of subjects: 8
Study 7586605 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 (1 microgram/kg BW)
Number of subjects: 8
Study 7586605 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GHRH1-29NH2 and GHRP-2 (1 microgram/kg BW each)
Number of subjects: 8
Study 1771378 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucin-containing saliva substitute
Number of subjects: 0
Study 1771378 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC)-containing saliva substitute
Number of subjects: 0
Study 1771378 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 6721668 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual psychotherapy
Number of subjects: 64
Study 6721668 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 64
Study 6721668 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint psychotherapy
Number of subjects: 64
Study 6721668 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 64
Study 30234528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound group
Number of subjects: 80
Study 30234528 — intervention group
Group type: COMPARATOR
Intervention: Landmark group
Number of subjects: 80
Study 30646314 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocarnitine (18 g)
Number of subjects: 250
Study 30646314 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocarnitine (12 g)
Number of subjects: 250
Study 30646314 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocarnitine (6 g)
Number of subjects: 250
Study 30646314 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 250
Study 27894328 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving pressure (ΔPrs)
Number of subjects: 787
Study 27894328 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateau pressure (Pplat,rs)
Number of subjects: 787
Study 27894328 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance (Crs)
Number of subjects: 787
Study 27894328 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Number of subjects: 787
Study 27894328 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume (VT)
Number of subjects: 787
Study 24498404 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based physical activity program (KISS) including daily physical education (two additional lessons per week), short physical activity breaks, and daily physical activity homework.
Number of subjects: 502
Study 24498404 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 502
Study 22625433 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsiflexion ankle orthosis during the 6-minute walk test (6MWT)
Number of subjects: 40
Study 22625433 — intervention group
Group type: COMPARATOR
Intervention: 6-minute walk test (6MWT) without the dorsiflexion ankle orthosis
Number of subjects: 40
Study 20067609 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan treatment
Number of subjects: 330
Study 21945258 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg of hemagglutinin antigen without adjuvant
Number of subjects: 266
Study 21945258 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg of hemagglutinin antigen with aluminum hydroxide, MPL and squalene
Number of subjects: 266
Study 21945258 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 μg of hemagglutinin antigen with aluminum hydroxide and MPL
Number of subjects: 266
Study 21945258 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 μg of hemagglutinin antigen with aluminum hydroxide and squalene
Number of subjects: 266
Study 21945258 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 266
Study 16139656 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg/day
Number of subjects: 420
Study 16139656 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/day
Number of subjects: 420
Study 16139656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 11896424 — intervention group
Group type: EXPERIMENTAL
Intervention: DHAP regimen
Number of subjects: 72
Study 11896424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPM) 5 g/m(2)
Number of subjects: 72
Study 11896424 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mobilization chemotherapy regimens (DHAP or CPM)
Number of subjects: 72
Study 11896424 — intervention group
Group type: EXPERIMENTAL
Intervention: DHAP
Number of subjects: 72
Study 9588637 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol via jet nebuliser (JN)
Number of subjects: 160
Study 9588637 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol via pressurised metered dose inhaler (PMDI)
Number of subjects: 160
Study 7905937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 2%
Number of subjects: 37
Study 7905937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 3%
Number of subjects: 37
Study 7905937 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 0%
Number of subjects: 37
Study 7905937 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 1%
Number of subjects: 37
Study 3178370 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride
Number of subjects: 340
Study 3178370 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 340
Study 3178370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 340
Study 3178370 — intervention group
Group type: COMPARATOR
Intervention: Bendroflumethiazide
Number of subjects: 340
Study 28624918 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim lighting with light instrumental music (modified group, 30 patients)
Number of subjects: 60
Study 28624918 — intervention group
Group type: COMPARATOR
Intervention: No music and standard lighting (standard group, 30 patients)
Number of subjects: 60
Study 26942657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Shower (CS) at 20.8°C ± 0.80°C for 15 minutes
Number of subjects: 17
Study 26942657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Shower (CS)
Number of subjects: 17
Study 26942657 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) condition (seated in the chamber for 15 minutes)
Number of subjects: 17
Study 25903450 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored program of ≥150 min of moderate- to vigorous-intensity physical activity per week for 6 months
Number of subjects: 41
Study 23065350 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Power
Number of subjects: 245
Study 20356487 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-based triple therapy (rabeprazole 10 mg twice a day, moxifloxacin 400 mg/day, amoxicillin 1000 mg twice a day)
Number of subjects: 109
Study 20356487 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-based quadruple therapy (rabeprazole 10 mg twice a day, bismuth salts 150 mg three times a day, clarithromycin 500 mg twice a day, metronidazole 400 mg twice a day)
Number of subjects: 109
Study 18055472 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (approximately 10 mg/kg every 4 weeks)
Number of subjects: 431
Study 18055472 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg every 8 weeks)
Number of subjects: 431
Study 18055472 — intervention group
Group type: COMPARATOR
Intervention: Placebo (every 4 weeks)
Number of subjects: 431
Study 18055472 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 431
Study 18055472 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 431
Study 16035956 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg/d)
Number of subjects: 28
Study 16035956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 12514674 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C infusion with furosemide
Number of subjects: 27
Study 12514674 — intervention group
Group type: COMPARATOR
Intervention: Furosemide alone
Number of subjects: 27
Study 12514674 — intervention group
Group type: COMPARATOR
Intervention: Furosemide with placebo
Number of subjects: 27
Study 12514674 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide with vitamin C and kallikrein inhibitor (nafamostat mesilate)
Number of subjects: 27
Study 10826586 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic spray
Number of subjects: 51
Study 10826586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 9015941 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 27
Study 9015941 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 27
Study 1740599 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program + support group (Group A)
Number of subjects: 32
Study 1740599 — intervention group
Group type: COMPARATOR
Intervention: Education program (Group B)
Number of subjects: 32
Study 1740599 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Group C)
Number of subjects: 32
Study 6541512 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated granules (EG)
Number of subjects: 12
Study 6541512 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional enteric-coated tablet (ET)
Number of subjects: 12
Study 6541512 — intervention group
Group type: COMPARATOR
Intervention: Conventional aspirin (control)
Number of subjects: 12
Study 31096259 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (CH)
Number of subjects: 198
Study 31096259 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin‐modified GIC (RMGIC)
Number of subjects: 198
Study 31096259 — intervention group
Group type: COMPARATOR
Intervention: No liner (DC)
Number of subjects: 198
Study 29948188 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (escitalopram)
Number of subjects: 38
Study 26578117 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 90
Study 26578117 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 90
Study 25181575 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 μg of phylloquinone daily for 12 months (with Ca 500 mg/d and vitamin D3 10 μg/d)
Number of subjects: 43
Study 25181575 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with Ca 500 mg/d and vitamin D3 10 μg/d)
Number of subjects: 43
Study 23700589 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted learning (CAL) module
Number of subjects: 0
Study 23700589 — intervention group
Group type: COMPARATOR
Intervention: Traditional text-/image-based learning supplements
Number of subjects: 0
Study 20506534 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OA group
Number of subjects: 95
Study 20506534 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic group
Number of subjects: 95
Study 20506534 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 95
Study 17963865 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm with 6% CS gel
Number of subjects: 119
Study 17963865 — intervention group
Group type: COMPARATOR
Intervention: Diaphragm with KY gel
Number of subjects: 119
Study 17963865 — intervention group
Group type: COMPARATOR
Intervention: CS gel alone
Number of subjects: 119
Study 15987488 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone
Number of subjects: 19
Study 15987488 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 11983451 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily interferon alfa-2b (3 million units per day for 12 weeks then 3 million units three times per week for 24 weeks) and ribavirin (36 week treatment)
Number of subjects: 321
Study 11983451 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b three times a week (alone or in combination with ribavirin)
Number of subjects: 321
Study 11983451 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa-2b alone
Number of subjects: 321
Study 9802051 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention during high-dose chemotherapy (48 hours of high-dose cyclophosphamide)
Number of subjects: 33
Study 9802051 — intervention group
Group type: COMPARATOR
Intervention: Usual antiemetic protocol (control group)
Number of subjects: 33
Study 7706152 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice output communication aid (VOCA)
Number of subjects: 1
Study 7706152 — intervention group
Group type: COMPARATOR
Intervention: Traditional staff management programs
Number of subjects: 1
Study 2545454 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg day‐1)
Number of subjects: 20
Study 2545454 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg day‐1)
Number of subjects: 20
Study 2545454 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Hydrochlorothiazide and Enalapril
Number of subjects: 20
Study 2545454 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 20
Study 2545454 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 20
Study 200435 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosazepam 100 mg
Number of subjects: 8
Study 200435 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 8
Study 200435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31512716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-based anaesthetic regimen (1-3% sevoflurane inhalation during anaesthesia maintenance)
Number of subjects: 42
Study 31512716 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based anaesthetic regimen (6-10 mg/kg/h propofol infusion during anaesthesia maintenance)
Number of subjects: 42
Study 30497087 — intervention group
Group type: EXPERIMENTAL
Intervention: FVL echoendoscope
Number of subjects: 126
Study 30497087 — intervention group
Group type: COMPARATOR
Intervention: CLA echoendoscope
Number of subjects: 126
Study 28664557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy (O2)
Number of subjects: 87
Study 28664557 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 87
Study 24931823 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 40
Study 24931823 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40
Study 24498845 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelladaghi herbal extract (suppository) administered every 12 hours from 24 hours before to 24 hours after surgery.
Number of subjects: 90
Study 24498845 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelladaghi herbal extract (oral) administered from 24 hours before to 24 hours after surgery.
Number of subjects: 90
Study 24498845 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered from 24 hours before to 24 hours after surgery.
Number of subjects: 90
Study 20887365 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide (3,200 mg/day)
Number of subjects: 357
Study 20887365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study 19762663 — intervention group
Group type: EXPERIMENTAL
Intervention: Active household water filtration devices
Number of subjects: 988
Study 19762663 — intervention group
Group type: COMPARATOR
Intervention: Sham household water filtration devices
Number of subjects: 988
Study 17556686 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose test meal
Number of subjects: 14
Study 17556686 — intervention group
Group type: COMPARATOR
Intervention: Glucose test meal
Number of subjects: 14
Study 15329830 — intervention group
Group type: COMPARATOR
Intervention: Doxylamine-pyridoxine combination (5-12 tablets/day)
Number of subjects: 376
Study 15329830 — intervention group
Group type: COMPARATOR
Intervention: Doxylamine-pyridoxine combination (1-4 tablets/day)
Number of subjects: 376
Study 15329830 — intervention group
Group type: EXPERIMENTAL
Intervention: No NVP
Number of subjects: 376
Study 11432893 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 0.5 mg/m²/d and carboplatin AUC of 4
Number of subjects: 0
Study 11432893 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 0.5 mg/m²/d and carboplatin AUC of 5
Number of subjects: 0
Study 11432893 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 0.75 mg/m²/d and carboplatin AUC of 5
Number of subjects: 0
Study 11432893 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 1.0 mg/m²/d and carboplatin AUC of 5
Number of subjects: 0
Study 11432893 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 1 mg/m²/d and carboplatin AUC of 5
Number of subjects: 0
Study 9058634 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30mg
Number of subjects: 12
Study 9058634 — intervention group
Group type: COMPARATOR
Intervention: pantoprazole 40mg
Number of subjects: 12
Study 8345497 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (atenolol, nifedipine, captopril)
Number of subjects: 25
Study 8345497 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 25
Study 8345497 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 25
Study 8345497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3453186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program focusing on nutrition, physical fitness, and cigarette smoking prevention
Number of subjects: 1822
Study 3453186 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1822
Study 30879163 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocystis sp. positive cases
Number of subjects: 340
Study 30879163 — intervention group
Group type: COMPARATOR
Intervention: Blastocystis sp. negative controls
Number of subjects: 340
Study 30514378 — intervention group
Group type: EXPERIMENTAL
Intervention: OPEN ARCH intervention (comprehensive, multidimensional geriatric assessment with care coordination)
Number of subjects: 100
Study 30514378 — intervention group
Group type: EXPERIMENTAL
Intervention: OPEN ARCH intervention
Number of subjects: 100
Study 30514378 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 27091810 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus aflibercept (4 mg/kg)
Number of subjects: 236
Study 27091810 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 alone
Number of subjects: 236
Study 24439981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 3319
Study 22108774 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg once daily (first dose 400 mg) for 5 days
Number of subjects: 12
Study 22108774 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole 100 mg twice daily (first dose 200 mg) for 5 days
Number of subjects: 12
Study 22108774 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 5 days
Number of subjects: 12
Study 20186679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacron graft
Number of subjects: 85
Study 20186679 — intervention group
Group type: COMPARATOR
Intervention: ePTFE graft
Number of subjects: 85
Study 17514541 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological awareness group
Number of subjects: 42
Study 17514541 — intervention group
Group type: COMPARATOR
Intervention: Language stimulation group
Number of subjects: 42
Study 15516364 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (15 g down to 2.5 g daily)
Number of subjects: 22
Study 15516364 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 22
Study 14533141 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran plus pindolol
Number of subjects: 80
Study 14533141 — intervention group
Group type: COMPARATOR
Intervention: Milnacipran plus placebo
Number of subjects: 80
Study 11206017 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label dalteparin, administered before percutaneous coronary intervention within 7 days
Number of subjects: 0
Study 11206017 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive approach
Number of subjects: 0
Study 8789431 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin alone (Roaccutan, Roche) 1 mg/kgr orally daily for 3 months or until remission achieved
Number of subjects: 57